

# CITATION REPORT

List of articles citing

**A compact VEGF signature associated with distant metastases and poor outcomes**

**DOI: 10.1186/1741-7015-7-9**  
**BMC Medicine, 2009, 7, 9.**

**Source:** <https://exaly.com/paper-pdf/45877927/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
155	Bevacizumab and breast cancer: current therapeutic progress and future perspectives. <b>2009</b> , 9, 1715-25		16
154	Proteomics, pathway array and signaling network-based medicine in cancer. <b>2009</b> , 4, 20		50
153	Distant metastasis: not out of reach any more. <b>2009</b> , 8, 28		10
152	Molecular markers of breast axillary lymph node metastasis. <b>2009</b> , 9, 441-54		15
151	Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer. <b>2010</b> , 3, 44		22
150	Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 2655-64	10.1	41
149	Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. <b>2010</b> , 24, 4648-59		76
148	SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. <b>2010</b> , 10, 703-11		27
147	Molecular stratification of triple-negative breast cancers. <i>Oncologist</i> , <b>2010</b> , 15 Suppl 5, 39-48	5.7	173
146	A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. <b>2010</b> , 9, 185		74
145	Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. <b>2011</b> , 178, 861-71		40
144	Signaling pathways in breast cancer metastasis - novel insights from functional genomics. <b>2011</b> , 13, 206		34
143	A clinically relevant gene signature in triple negative and basal-like breast cancer. <b>2011</b> , 13, R97		238
142	Clinical implementation of RNA signatures for pharmacogenomic decision-making. <b>2011</b> , 4, 95-107		1
141	Blood-brain barrier integrity and breast cancer metastasis to the brain. <b>2010</b> , 2011, 920509		50
140	Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. <i>PLoS ONE</i> , <b>2011</b> , 6, e28403	3.7	63
139	ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. <b>2011</b> , 118, 3990-4002		157

138	Vascular proliferation is increased in basal-like breast cancer. <b>2011</b> , 130, 1063-71		39
137	Quantitative single-cell gene expression measurements of multiple genes in response to hypoxia treatment. <b>2011</b> , 401, 3-13		11
136	Polymorphisms in the 5R and 3Runtranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. <b>2011</b> , 32, 295-300		28
135	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. <b>2011</b> , 4, 3		104
134	Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. <b>2011</b> , 10, 1772-83		310
133	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. <b>2011</b> , 25, 199-211		118
132	Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?. <b>2011</b> , 29, e18-20		152
131	Molecular stratification of triple-negative breast cancers. <i>Oncologist</i> , <b>2011</b> , 16 Suppl 1, 61-70	5-7	247
130	Biphasic effect of curcumin on morphine tolerance: a preliminary evidence from cytokine/chemokine protein array analysis. <b>2011</b> , 2011, 452153		11
129	Systems biology and genomics of breast cancer. <b>2011</b> , 3,		127
128	Angiopoietin-like 4: a decade of research. <b>2012</b> , 32, 211-9		171
127	The role of targeted therapy and biomarkers in breast cancer treatment. <b>2012</b> , 29, 807-19		30
126	The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. <b>2012</b> , 102, 436-43		37
125	Stem Cell Characters in Primary and Metastatic Tumour Establishment. <b>2012</b> , 533-580		1
124	Characterization of basal-like breast cancer: an update. <b>2012</b> , 18, 104-111		12
123	Growth factor signaling in metastasis: current understanding and future opportunities. <b>2012</b> , 31, 479-91		23
122	Exposure to ionizing radiation induced persistent gene expression changes in mouse mammary gland. <b>2012</b> , 7, 205		22
121	Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. <i>PLoS ONE</i> , <b>2012</b> , 7, e45394	3-7	21

120	Tumor angiogenesis: pericytes and maturation are not to be ignored. <b>2012</b> , 2012, 261750		33
119	Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. <b>2012</b> , 22, 246-58		385
118	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. <b>2012</b> , 132, 523-35		165
117	B-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. <b>2013</b> , 13, 128		27
116	Inverse PPAR $\gamma$ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. <b>2013</b> , 32, 5241-52		64
115	Adrenomedullin gene dosage correlates with tumor and lymph node lymphangiogenesis. <b>2013</b> , 27, 590-600		24
114	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. <i>Scientific Reports</i> , <b>2013</b> , 3, 3544	4.9	42
113	Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e71915	3.7	49
112	An 18-gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e98787	3.7	16
111	Plakophilins in desmosomal adhesion and signaling. <b>2014</b> , 21, 25-42		38
110	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. <b>2014</b> , 6, 1542-60		80
109	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. <b>2014</b> , 31, 33-45		38
108	The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4. <b>2014</b> , 17, 261-74		42
107	Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. <i>BMC Bioinformatics</i> , <b>2014</b> , 15, 170	3.6	19
106	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <b>2014</b> , 146, 557-66		48
105	An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. <b>2014</b> , 46, 1051-9		158
104	Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. <i>Molecular Oncology</i> , <b>2014</b> , 8, 431-43	7.9	36
103	ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 41360-9	3.3	17

102	Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. <i>Oncotarget</i> , <b>2015</b> , 6, 39676-91	3.3	75
101	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. <i>Oncotarget</i> , <b>2015</b> , 6, 12890-908	3.3	80
100	Lentinula edodes-derived polysaccharide enhances systemic and mucosal immunity by spatial modulation of intestinal gene expression in mice. <b>2015</b> , 6, 2068-80		13
99	Adrenomedullin in lymphangiogenesis: from development to disease. <b>2015</b> , 72, 3115-26		18
98	Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin. <i>Biomedicine and Pharmacotherapy</i> , <b>2015</b> , 69, 162-9	7.5	24
97	Changes in prevalence of chronic obstructive pulmonary disease and asthma in the US population and associated risk factors. <b>2015</b> , 12, 47-60		37
96	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1081-90	7.9	25
95	Role of Small Heat Shock Protein HspB5 in Cancer. <b>2015</b> , 301-314		1
94	Prognostic stromal gene signatures in breast cancer. <b>2015</b> , 17, 23		60
93	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. <b>2015</b> , 17, 43		171
92	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <b>2015</b> , 7, 283ra51		204
91	Gene Expression Signatures as Biomarkers of Tumour Hypoxia. <b>2015</b> , 27, 547-60		74
90	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. <b>2016</b> , 9, 431-44		42
89	Long-term exercise training as a modulator of mammary cancer vascularization. <i>Biomedicine and Pharmacotherapy</i> , <b>2016</b> , 81, 273-280	7.5	28
88	Review on near-infrared heptamethine cyanine dyes as theranostic agents for tumor imaging, targeting, and photodynamic therapy. <b>2016</b> , 21, 50901		147
87	The downregulation of ANGPTL4 inhibits the migration and proliferation of tongue squamous cell carcinoma. <b>2016</b> , 71, 144-149		15
86	Evaluation of vascular endothelial growth factor gene and protein expression in canine metastatic mammary carcinomas. <b>2016</b> , 79, 1097-1104		5
85	Brief-exposure to preoperative bevacizumab reveals a TGF- $\beta$ signature predictive of response in HER2-negative breast cancers. <b>2016</b> , 138, 747-57		12

84	Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4067-76	12.9	30
83	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. <i>Molecular Oncology</i> , <b>2016</b> , 10, 1169-82	7.9	38
82	Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. <b>2016</b> , 34, 542-9		242
81	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 2213-2221	10.1	109
80	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <b>2017</b> , 8, 1392-1407		53
79	G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. <b>2017</b> , 114, 7077-7082		72
78	Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. <b>2017</b> , 544, 250-254		365
77	PPAR $\alpha$ in human cancer. <b>2017</b> , 136, 90-99		25
76	Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. <b>2017</b> , 19, 684-694		11
75	Gene Expression Signatures of the Tumor Microenvironment: Relation to Tumor Progress in Breast Cancer. <b>2017</b> , 379-407		
74	The Application of Heptamethine Cyanine Dye DZ-1 and Indocyanine Green for Imaging and Targeting in Xenograft Models of Hepatocellular Carcinoma. <b>2017</b> , 18,		23
73	Multiple Roles of Angiopoietin-Like 4 in Osteolytic Disease. <b>2017</b> , 8, 80		13
72	PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes. <b>2017</b> , 2, e87380		25
71	Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice. <b>2018</b> , 184, 186-195		8
70	An assessment of prognostic immunity markers in breast cancer. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 35	7.8	22
69	Prediction of early breast cancer patient survival using ensembles of hypoxia signatures. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204123	3.7	7
68	Intracellular hypoxia measured by F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. <b>2018</b> , 20, 78		13
67	NDRG1 regulates neutral lipid metabolism in breast cancer cells. <b>2018</b> , 20, 55		32

66	Gene expression in triple-negative breast cancer in relation to survival. <b>2018</b> , 171, 199-207		23
65	Angiopoietin-like 4 promotes osteosarcoma cell proliferation and migration and stimulates osteoclastogenesis. <b>2018</b> , 18, 536		20
64	Intra-individual Gene Expression Variability of Histologically Normal Breast Tissue. <i>Scientific Reports</i> , <b>2018</b> , 8, 9137	4.9	3
63	Intratumoral heterogeneity and hypoxia gene expression signatures: Is a single biopsy adequate?. <b>2019</b> , 19, 110-115		7
62	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. <b>2019</b> , 12,		5
61	Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. <b>2019</b> , 1, 431-444		76
60	Mapping Metabolic Events in the Cancer Cell Cycle Reveals Arginine Catabolism in the Committed SGM Phase. <b>2019</b> , 26, 1691-1700.e5		17
59	OSBrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1349	5.3	15
58	A transcriptome-based signature of pathological angiogenesis predicts breast cancer patient survival. <b>2019</b> , 15, e1008482		7
57	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. <b>2020</b> , 146, 262-271		17
56	Research-based PAM50 signature and long-term breast cancer survival. <b>2020</b> , 179, 197-206		25
55	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 65, 140-154	12.7	30
54	Hypoxia-Associated Prognostic Markers and Competing Endogenous RNA Co-Expression Networks in Breast Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 579868	5.3	14
53	ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis. <i>Current Opinion in Hematology</i> , <b>2020</b> , 27, 206-213	3.3	21
52	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. <i>Oncologist</i> , <b>2020</b> , 25, e1481-e1491	5.7	27
51	Heterogeneity and vascular permeability of breast cancer brain metastases. <i>Cancer Letters</i> , <b>2020</b> , 489, 174-181	9.9	8
50	Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer. <i>Molecular Oncology</i> , <b>2020</b> , 14, 2814-2833	7.9	26
49	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1896-1904	12.9	7

48	Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. <i>Scientific Reports</i> , <b>2020</b> , 10, 2914	4.9	5
47	Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 3095	8.4	13
46	Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy. <i>Antioxidants and Redox Signaling</i> , <b>2021</b> , 34, 1484-1497	8.4	19
45	Angiopoietin-like protein 4 is a chromatin-bound protein that enhances mammosphere formation and experimental triple-negative breast cancer brain and liver metastases. <i>Journal of Carcinogenesis</i> , <b>2021</b> , 20, 8	1.9	1
44	Targeting BRF2 in Cancer Using Repurposed Drugs. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
43	Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 139, 111607	7.5	6
42	Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics.		1
41	DNA methylation mediated down-regulation of ANGPTL4 promotes colorectal cancer metastasis by activating the ERK pathway. <i>Journal of Cancer</i> , <b>2021</b> , 12, 5473-5485	4.5	1
40	Breast Cancer Liver Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , <b>2011</b> , 273-303		2
39	Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. <i>PLoS ONE</i> , <b>2010</b> , 5, e10421	3.7	27
38	Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. <i>PLoS ONE</i> , <b>2011</b> , 6, e22469	3.7	19
37	Negative regulation of NF- $\kappa$ B by the ING4 tumor suppressor in breast cancer. <i>PLoS ONE</i> , <b>2012</b> , 7, e46823	3.7	31
36	Specific extracellular matrix remodeling signature of colon hepatic metastases. <i>PLoS ONE</i> , <b>2013</b> , 8, e74599	3.7	32
35	A core program of gene expression characterizes cancer metastases. <i>Oncotarget</i> , <b>2017</b> , 8, 102161-102175	3.3	15
34	Integrated landscape of copy number variation and RNA expression associated with nodal metastasis in invasive ductal breast carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 36836-36848	3.3	7
33	Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 10634-45	3.3	13
32	Deregulation of PPAR $\alpha$ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. <i>Oncotarget</i> , <b>2015</b> , 6, 13416-33	3.3	58
31	Gene expression in "young adult type" breast cancer: a retrospective analysis. <i>Oncotarget</i> , <b>2015</b> , 6, 13688-702	3.0	29



30 Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). *Oncotarget*, **2016**, 7, 18953-64 3.3 9

29 Molecular Classification of Breast Carcinoma. **2012**, 365-379

28 Prediction of early breast cancer patient survival using ensembles of hypoxia signatures.

27 RadiationGeneSigDB: A database of oxic and hypoxic radiation response gene signatures and their utility in identification of hypoxia-regulated MicroRNA.

26 The evolution and ecology of benign tumors. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1877, 188643 11.2 0

25 Modelling of hypoxia gene expression for three different cancer cell lines. *International Journal of Computational Biology and Drug Design*, **2020**, 13, 124-143 0.4

24 Hypoxia classifier for transcriptome datasets.

23 Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. *Npj Breast Cancer*, **2021**, 7, 145 7.8 0

22 Neurogenesis and angiogenesis are associated features of aggressive breast cancer.

21 Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up.. *British Journal of Cancer*, **2022**, 8.7 2

20 Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.. *Cancer Research*, **2022**, 82, 1174-1192 10.1 3

19 DataSheet\_1.docx. **2020**,

18 Image\_1.tif. **2020**,

17 Image\_2.tif. **2020**,

16 Table\_1.xls. **2020**,

15 Table\_2.xlsx. **2020**,

14 Table\_3.xls. **2020**,

13 Table\_4.xlsx. **2020**,

12 Table\_5.xlsx. **2020**,

11 Table\_6.xlsx. **2020**,

10 Table\_1.XLSX. **2019**,

9 Hypoxia classifier for transcriptome datasets. *BMC Bioinformatics*, **2022**, 23,

3.6 ○

8 Gene Expression Signatures of the Tumor Microenvironment: Relation to Tumor Phenotypes and Progress in Breast Cancer. **2022**, 401-424

7 Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis. **2022**, 101, e29877 ○

6 Obesity and cancer: Extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases. **2022**, 41, 517-547

1

5 Harnessing Antibody Polyspecificity for Cancer Immunotherapy. **2022**, 41, 290-300 ○

4 Pan-cancer analysis of tissue and single-cell HIF-pathway activation using a conserved gene signature. **2022**, 41, 111652 ○

3 A subnetwork-based framework for prioritizing and evaluating prognostic gene modules from cancer transcriptome data. **2023**, 26, 105915 ○

2 Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. **2023**, 14, ○

1 signfinder enables the identification of tumor cell states and cancer expression signatures in bulk, single-cell and spatial transcriptomic data. ○